Our MISSION is to translate our circulating cell-free DNA (cfDNA) in urine technology into improved cancer screening and management by liquid biopsy towards our VISION of decreased global cancer mortality.
- Frank Wei Song, M.D., Ph.D., Founder & President, board-certified practice medical oncologist
- Selena Lin, Ph.D., Interim COO
- Kathleen Czupich, M.B.A., Director, Business Development and Management
- Ying-Hsiu Su, Ph.D., Interim CSO, pioneering in urine circulating cfDNA research
Scientific Advisory Board
Frank Wei Song, M.D., Ph.D., Chair
- President and Founder, JBS Science Inc
- Director, Pottstown Cancer Center
- Hematologist/Medical Oncologist
Ying-Hsiu Su, Ph.D.
- Professor, Translational Medical Science at BSBI
Chief, Laboratory for Early Cancer detection
Martin E. Adelson, Ph.D.
- COO, Genesis Biotechnology Group
Di Chen, Ph.D.
- CEO, ClinPharm Inc., Biomarker biostatistician
Koon Yan (Chris) Pak, Ph.D.
- CEO and Founder, Molecular Targeting Technologies, Inc.
Surbhi Jain, M.D., Ph.D.
- Expert in specialized cfDNA marker assays
© 2020 JBS Science. All rights reserved.